These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21875319)

  • 1. The effectiveness of recombinant human erythropoietin (EPO) treatment in a neonate with hyporegenerative anemia following Rh isoimmunization in spite of normal serum Epo level.
    Erduran E; Bahadir A
    Pediatr Hematol Oncol; 2011 Nov; 28(8):721-2. PubMed ID: 21875319
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-Rh(c), "little c," isoimmunization: the role of rHuEpo in preventing late anemia.
    Zuppa AA; Cardiello V; Alighieri G; Cota F; D'Antuono A; Riccardi R; Catenazzi P; Romagnoli C
    J Pediatr Hematol Oncol; 2013 Aug; 35(6):e269-71. PubMed ID: 23073047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemolytic disease.
    Ohls RK; Wirkus PE; Christensen RD
    Pediatrics; 1992 Nov; 90(5):678-80. PubMed ID: 1408538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin as treatment for late hyporegenerative anemia in neonates with Rh hemolytic disease after in utero exchange transfusion.
    Nicaise C; Gire C; Casha P; d'Ercole C; Chau C; Palix C
    Fetal Diagn Ther; 2002; 17(1):22-4. PubMed ID: 11803211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe late onset anaemia following intrauterine transfusion.
    Fillon G; Heaton PA; Paul SP
    Br J Hosp Med (Lond); 2016 Oct; 77(10):600-601. PubMed ID: 27723391
    [No Abstract]   [Full Text] [Related]  

  • 6. Hyporegenerative anemia associated with Rh hemolytic disease: treatment failure of recombinant erythropoietin.
    Pessler F; Hart D
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):689-93. PubMed ID: 12439047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fetal plasma erythropoietin concentration during intrauterine transfusion therapy in isoimmunohemolytic anemia due to rhesus incompatibility].
    Hebgen A; Schiffer-N'Gampolo D; Bald R; Hansmann M; Bode U
    Ultraschall Med; 1997 Aug; 18(4):162-4. PubMed ID: 9381123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin in the prevention of late anemia in intrauterine transfused neonates with Rh-isoimmunization.
    Zuppa AA; Alighieri G; Calabrese V; Visintini F; Cota F; Carducci C; Antichi E; Noia GA; Fortunato G; Romagnoli C
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):e95-101. PubMed ID: 20216236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe hemolytic disease of the newborn due to anti-Cw.
    Byers BD; Gordon MC; Higby K
    Obstet Gynecol; 2005 Nov; 106(5 Pt 2):1180-2. PubMed ID: 16260563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin production by macrophages from preterm infants: implications regarding the cause of the anemia of prematurity.
    Ohls RK; Li Y; Trautman MS; Christensen RD
    Pediatr Res; 1994 Feb; 35(2):169-70. PubMed ID: 8165050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of recombinant human erythropoietin (EPO-alfa) in a mother alloimmunized to the Js(b) antigen.
    Santolaya-Forgas J; Vengalil S; Duval J; Gottmann D; Meyer W; Gauthier D; DeChristopher PJ
    J Matern Fetal Med; 1999; 8(3):141-5. PubMed ID: 10338071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin in human fetuses with immune hemolytic anemia and hydrops fetalis.
    Moya FR; Grannum PA; Widness JA; Clemons GK; Copel JA; Hobbins JC
    Obstet Gynecol; 1993 Sep; 82(3):353-8. PubMed ID: 8355933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of neonatal Rh disease.
    Peterec SM
    Clin Perinatol; 1995 Sep; 22(3):561-92. PubMed ID: 8521682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic growth factors: Part II.
    Wandstrat TL; Wolfe M
    Neonatal Netw; 1996 Oct; 15(7):25-8. PubMed ID: 9035641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intravascular, intrauterine transfusion on prenatal and postnatal hemolysis and erythropoiesis in severe fetal isoimmunization.
    Millard DD; Gidding SS; Socol ML; MacGregor SN; Dooley SL; Ney JA; Stockman JA
    J Pediatr; 1990 Sep; 117(3):447-54. PubMed ID: 2118174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late hyporegenerative anemia in neonates with rhesus hemolytic disease.
    al-Alaiyan S; al Omran A
    J Perinat Med; 1999; 27(2):112-5. PubMed ID: 10379500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia of prematurity: the prospects for avoiding blood transfusions by treatment with recombinant human erythropoietin.
    Dallman PR
    Adv Pediatr; 1993; 40():385-403. PubMed ID: 8249712
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyporegenerative anemia and other complications of rhesus hemolytic disease: to treat or not to treat is the question.
    Alaqeel AA
    Pan Afr Med J; 2019; 32():120. PubMed ID: 31223410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study comparing recombinant erythropoietin alone with erythropoietin plus recombinant granulocyte-macrophage colony-stimulating factor for treatment of the anemia of prematurity.
    Christensen RD; Hunter DD; Ohls RK
    J Perinatol; 1994; 14(2):110-3. PubMed ID: 8014692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study.
    Soubasi V; Kremenopoulos G; Diamandi E; Tsantali C; Tsakiris D
    Pediatr Res; 1993 Nov; 34(5):675-9. PubMed ID: 8284109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.